Working… Menu

RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01188889
Recruitment Status : Withdrawn (Unable to obtain sufficient funding.)
First Posted : August 26, 2010
Last Update Posted : May 15, 2015
Information provided by (Responsible Party):
University of Michigan Rogel Cancer Center

Brief Summary:
Patients participating in this study will have a diagnosis of Chronic Myeloid Leukemia. This study will evaluate whether the addition of an investigational drug called RAD001 given together with Imatinib will better target leukemia stem cells, causing them to die. Stem cells are a small population of cells, existing primarily within the bone marrow, and are believed to be responsible for the ongoing risk of disease relapse.

Condition or disease Intervention/treatment Phase
Chronic Myeloid Leukemia Drug: RAD001 Drug: Imatinib Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label, Time-To-Event Continuous Reassessment Method, Phase I/II Study of the Mammalian Target of Rapamycin (mTOR) Inhibitor RAD001 in Combination With Imatinib (Gleevec) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) With Persistent Molecular Disease.
Study Start Date : September 2013
Estimated Primary Completion Date : December 2016
Estimated Study Completion Date : December 2017

Intervention Details:
  • Drug: RAD001

    Dosing schedule of RAD001 for the Phase I portion:

    Regimen 1. 5.0 mg q72 hours (400 mg QD); Regimen 2. 5 mg q48 hours (400 mg QD); Regimen 3. 5.0 mg q day (400 mg QD); Regimen 4. 7.5 mg PO q day (400 mg QD.

  • Drug: Imatinib
    Imatinib will be given continuously at a fixed daily dose of 400 mg once daily.
    Other Name: Gleevac

Primary Outcome Measures :
  1. The primary objective will assess for the maximum tolerated dose of RAD001 when combined with a fixed dose of Imatinib. [ Time Frame: This objective will assessed by a time-to-event, continuous reassessment method to establish the maximun tolerated dose of the combination of a fixed dose of Imatinib together with RAD001. ]

Secondary Outcome Measures :
  1. The objective will assess the degree to which a fixed dose of Imatinib combined with RAD001 given at the maximum tolerated dose is able to deplete the pool of minimal residual disease in patients. [ Time Frame: This objective will be assessed by RT-PCR for the Bcr-Abl gene product as demonstrated by the degree of complete molecular responses. ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Study subjects must be at least age 18 years or older.
  • Study subjects must have an Eastern Cooperative Oncology Group performance status 0-2.
  • Study subjects must provide a signed written informed consent.
  • Study subjects must be able to comply with study procedures and follow-up examinations.
  • Female study subjects: non-fertile (status post hysterectomy (removal of the uterus) or menopausal (no menstrual period) for 24 consecutive months or agree to use birth control during the study through the end of last treatment visit. Women of childbearing potential must have a negative serum pregnancy test within 3 days prior to administration of RAD001). Use of a single agent for prevention of pregnancy (oral, implantable, or injectable contraceptives) may be affected by medications that alter the activity of the cytochrome P450 enzyme, and are therefore, not considered effective during participation in this clinical trial.If there is ANY chance that pregnant can occur, there must be a commitment to continue abstinence from heterosexual intercourse or begin TWO methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME.
  • There must be at least two weeks since any major surgery, completion of radiation, or completion of all prior systemic anticancer therapy (adequately recovered from the acute toxicities of any prior therapy).

Study subjects must meet the following disease criteria:

  • Diagnosis of Chronic Myelogenous Leukemia according to the World Health Organization.
  • Persistent molecular disease as defined by the persistent identification of the Bcr-Abl transcript using quantitative RT-PCR on at least 2 occasions at least 3 months apart and having completed a minimum of 18 months of treatment with Imatinib at 400 mg once daily.
  • Achieved a complete cytogenetic response. (This shall be measured at least one time prior to consent to participation in the clinical trial, and shall be reassessed at the initiation of the clinical trial.)
  • Non-hematologic symptoms related to Imatinib therapy that are ≤ Grade 2 in severity for at least 6 months prior to enrollment.

Study subjects must meet the following organ function criteria:

  • Adequate bone marrow function
  • Adequate renal and hepatic function
  • International normalized ration <1.3 (or <3 on anticoagulants)

Study subjects must meet the following cardiac function criteria:

  • No history of uncontrolled angina, congestive heart failure or myocardial infarction within 6 months of study entry. If there is a suspected clinical history of coronary artery disease, then the patient must document one of the following within 1 year of study participation:Left ventricular ejection fraction greater than 40% on multigated acquisition scan or similar radionuclide angiographic scan; or Left ventricular fractional shortening greater than 22% on echocardiography exam; or LVEF greater than 40% on echocardiography exam.
  • No history of a diagnosis or suspected congenital QRS complex to the end of the T wave on an electrocardiogram syndrome.
  • No history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes).
  • No history of uncontrolled hypertension.

Exclusion Criteria:

  • Study subjects may not have had prior treatment with RAD001, sirolimus, temsirolimus, or rapamycin.
  • Study subjects may not have a known hypersensitivity to RAD001 or other rapamycin, sirolimus, temsirolimus or to its excipients.
  • Study subjects may not have received an investigational agent received within 28 days prior to the first dose of study drug.
  • Study subjects may not have psychiatric disorders that would interfere with consent, study participation, or follow-up.
  • Study subjects may not have a history of noncompliance to medical regimens.
  • Study subjects unwilling to or unable to comply with the protocol are not eligible to participate in this clinical research trial.

Study subjects that meet any of the following criteria are not eligible to participate in the clinical research study:

  • Diagnosis of an accelerated phase or a blast phase of chronic myeloid leukemia according to the World Health Organization criteria.
  • Clinical evidence suggestive of central nervous system involvement with leukemia unless a lumbar puncture confirms the absence of leukemia in the cerebrospinal fluid.
  • Prior hematopoietic stem cell transplant.
  • Prior external beam radiation therapy to the pelvis.
  • Diagnosis of another malignancy, unless disease-free for at least 3 years following the completion of curative intent therapy with the following exceptions: treatment of non-melanoma skin cancer, in situ carcinoma, or cervical intraepithelial neoplasia, regardless of the disease-free duration - with treatment for the condition complete.
  • Known chronic condition requiring the treatment with systemic steroids or another immunosuppressive agents.
  • Systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment).
  • Prior seropositive test for the human immunodeficiency virus.
  • Uncontrolled diabetes mellitus
  • Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001 (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection).
  • Any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver, or other organ system that may place the patient at undue risk to undergo therapy with RAD001 including:severely impaired lung function; liver disease such as cirrhosis, chronic active hepatitis or chronic; persistent hepatitis;other nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the treatment with the study therapy.
  • History of significant bleeding disorder unrelated to cancer, including:Congenital bleeding disorders (e.g., von Willebrand's disease); Acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01188889

Layout table for location information
United States, Michigan
University of Michigan Health System
Ann Arbor, Michigan, United States, 48109
Sponsors and Collaborators
University of Michigan Rogel Cancer Center
Layout table for investigator information
Principal Investigator: Dale Bixby, M.D., Ph.D. University of Michigan
Layout table for additonal information
Responsible Party: University of Michigan Rogel Cancer Center Identifier: NCT01188889    
Other Study ID Numbers: UMCC 2008.093
HUM 24993 ( Other Identifier: University of Michigan Medical IRB )
First Posted: August 26, 2010    Key Record Dates
Last Update Posted: May 15, 2015
Last Verified: May 2015
Keywords provided by University of Michigan Rogel Cancer Center:
Chronic Myeloid Leukemia
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Myeloid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid, Chronic-Phase
Neoplasms by Histologic Type
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases
Imatinib Mesylate
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs